Medication adherence among patients with advanced prostate cancer using oral therapies
| Autor: | Isabelle Ghelerter, Marie-Hélène Lafeuille, Mike Durkin, Joyce LaMori, Patrick Lefebvre, Lorie Ellis, Carmine Rossi, Dominic Pilon, Xuehua Ke |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Adolescent medicine.medical_treatment Abiraterone Acetate Administration Oral Antineoplastic Agents Pharmacy Drug Costs Medication Adherence Young Adult chemistry.chemical_compound Prostate cancer Quality of life Internal medicine Nitriles Phenylthiohydantoin Health care medicine Humans Enzalutamide Longitudinal Studies Aged Neoplasm Staging Retrospective Studies Chemotherapy business.industry Apalutamide Age Factors Abiraterone acetate Prostatic Neoplasms General Medicine Middle Aged medicine.disease Thiohydantoins Oncology chemistry Benzamides Quality of Life business |
| Zdroj: | Future Oncology. 18:231-243 |
| ISSN: | 1744-8301 1479-6694 |
| Popis: | Aims: In light of the extended overall survival and improved quality of life provided by advanced prostate cancer (PC) oral therapies, this study aimed to describe treatment adherence to advanced PC oral therapies and evaluate associated patient characteristics and subsequent healthcare resource utilization (HRU). Patients & methods: Patients with advanced PC initiating apalutamide, enzalutamide or abiraterone acetate were identified from administrative data (October 1, 2014–September 30, 2019). Adherence and persistence at six months postinitiation were used to evaluate patient factors and HRU. Results: Aged ≥75 years, Black race, chemotherapy use and higher pharmacy paid amounts were associated with poor adherence/persistence, which translated to higher HRU. Conclusions: Strategies to increase adherence and persistence may improve patient outcomes and associated HRU. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|